CANCER CENTER ADMINISTRATION - ABSTRACT Administration at the Karmanos Cancer Institute (KCI) provides support to the Cancer Center leadership, Research Program and Shared Resource infrastructure, KCI membership, and staff by providing services aimed at relieving the administrative burden associated with research. Administration contributes to the mission of the Cancer Center by providing efficient management of resources, facilitating key internal and external scientific meetings, strategic planning, and developing useful metrics to aid in the decision making of KCI senior leadership. Mr. Evano Piasentin, Associate Center Director for Research Administration, leads an experienced administrative team. Administration supports 135 scientific members across four research Programs and nine Shared Resources (including one under development). Additionally, Administration manages extramural funding of $63 million (annual direct costs), KCI?s annual research budget of $21 million, and coordinated internal pilot funding of more than $2 million since the last renewal. Notable achievements during the past funding period include a restructuring of the administrative office to capitalize on the unique skills of staff and provide a more efficient and dynamic environment to meet the needs of the Cancer Center. Additionally, Administration supported the planning, process, and development of a new strategic plan through organization of strategic planning retreats convening stakeholders from various disciplines across KCI. The strategic plan is centered on five priority areas: immunology and immunotherapy, cancer metabolism and metabolomics, biology of cancer health disparities, addressing multilevel determinants of risk and survivorship, and increasing interventional research to reduce disparities. Administration continues to implement significant upgrades to the Research Administration Application (RAA), a homegrown repository of CCSG data for KCI. With respect to space management, Administration managed a relocation of basic science laboratories from the outdated Prentis Cancer Research Building to the renovated Elliman Research Building. Finally, Administration played a central role in the development of several large, multi-PI project grants leading to the first-ever funded SPORE grant at KCI; The Michigan Prostate SPORE (P50CA186786).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088974
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298
An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319
Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238
Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993
Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240

Showing the most recent 10 out of 826 publications